Designer macrophages: Oxidative metabolism fuels inflammation repair  by Lacy-Hulbert, Adam & Moore, Kathryn J.
P R E V I E W SDesigner macrophages: Oxidative metabolism
fuels inflammation repair
Macrophages play a central role in immunity, contributing to both the initiation and resolution of inflammation. In this issue of
Cell Metabolism, Vats et al. provide insight into the mechanisms by which reparative macrophages are generated and reveal
a previously unappreciated link between this anti-inflammatory axis andmitochondrial oxidativemetabolism (Vats et al., 2006).Cytokines and other local tissue compo-
nents prime macrophages to adopt dis-
tinct activation states for the promotion
and attenuation of inflammation, and
disruption of this process may underlie
diseases as diverse as atherosclerosis,
cancer, and autoimmunity. The classical
pathway of macrophage activation in-
duced by interferon (IFN)-g in concert
with microbial stimuli (e.g., lipopolysac-
charide; LPS) or inflammatory cytokines
(e.g., tumor necrosis factor; TNF-a) has
been studied since the 1960s and is
known to play a vital role in host defense.
Macrophages activated in this manner
express high levels of proinflammatory
cytokines (e.g., TNF-a, and interleukins
[IL] 1b, 6, and 12) and reactive oxygen
and nitrogen intermediates that are po-
tent weapons in the defense against
intracellular pathogens and tumors.
Less well studied has been an alternative
pathway of activation that equips macro-
phages to limit inflammation and pro-
mote its resolution (Gordon, 2003). The
concept of alternative macrophage acti-
vation was first introduced in 1992
when macrophages exposed to IL-4,
a cytokine generally produced in T helper
2 (Th2) cell type responses, were shown
to have reduced inflammatory cytokine
secretion and to express high levels of
the mannose receptor (Stein et al.,
1992). Further characterization of this
phenotype has demonstrated that IL-4
and IL-13 induce an overlapping set of
markers that distinguish the alternatively
activated macrophage, such as distinct
repertoires of endocytic/phagocytic
receptors, immune effectors, and meta-
bolic programs. These include the
enzyme arginase I, which shifts arginine
utilization from the production of nitric
oxide by nitric oxide synthase 2 (iNOS)
to the production of polyamines and
proline, a key component of collagen
(Gordon, 2003). This type of activation
is believed to be an asset for the reso-
lution of inflammation by attenuating
excessive inflammation and stimulatingCELL METABOLISM : JULY 2006matrix synthesis to encourage the forma-
tion of granulomas and tissue repair.
Although harnessing macrophage polari-
zation to sculpt the inflammatory re-
sponse holds great therapeutic promise
for the treatment of diseases of chronic
or excessive inflammation, progress on
this front is limited by a current lack of un-
derstanding of the regulatory pathways
that control alternative macrophage acti-
vation and switching of activation pro-
grams. It now appears that the metabolic
pathways utilized by alternatively
activated macrophages and their anti-
inflammatory properties are tightly
coregulated, suggesting that metabolic
therapies may have direct effects on
immune responses (Vats et al., 2006).
In this issue of Cell Metabolism, Vats
et al. asked how alternative activation of
macrophages by IL-4 induces cellular
pathways for fatty-acid metabolism,
including fatty-acid uptake, fatty-acid
oxidation, and mitochondrial biogenesis,
and how these affect inflammatory re-
sponses. They highlight the importance
of this metabolic program in macrophage
polarization by demonstrating that phar-
macologic inhibition of cellular oxidative
metabolism potently suppresses the
effector functions of alternatively, but
not classically, activated macrophages.
Of particular interest, the authors show
that IL-4 induces expression of PPARg-
coactivator-1b (PGC-1b), a transcription
factor coactivator that enhances the ac-
tivity of the nuclear hormone receptor
family of transcription factors. PGC-1b,
and its homolog PGC-1a, have been de-
scribed as nuclear receptor ‘‘boosters’’
as they assemble a regulatory complex
on these receptors that enhances target
gene transcription by providing the enzy-
matic activities needed to modify chro-
matin, unwind DNA, and recruit RNA
polymerase II (Finck and Kelly, 2006).
Although originally identified as inducible
regulators of PPARg, these coactivators
have been shown to complex with mul-
tiple nuclear hormone receptor familymembers to regulate a range of meta-
bolic processes, including mitochondrial
biogenesis, cellular respiration rates,
and energy substrate uptake and utiliza-
tion (Finck and Kelly, 2006). Recently,
the list of PGC-1 interactors has ex-
panded further to include nonnuclear
receptor partners, such as myocyte
enhancer factor-2 (MEF-2), forkhead
box O1 (FOXO1), and Sterol Regulatory
Element Binding Protein-1 (SREBP1),
suggesting that these coactivators may
have pleiotropic functions (Finck and
Kelly, 2006). This work from Chawla’s
group (Vats et al., 2006) adds a new tran-
scription factor partner to this list, STAT6,
which has previously been shown to be
activated by both IL-4 and IL-3 during
alternative macrophage programming
(Rutschman et al., 2001).
Interestingly, the authors show that
a feedforward loop, in which PGC-1b is
induced by and coactivates STAT6, am-
plifies the metabolic, biogenic, and anti-
inflammatory programs of alternatively
activated macrophages (Vats et al.,
2006) (Figure 1). PGC-1b strongly en-
hances STAT6-induced arginase 1 pro-
moter activity and coprecipitates with
STAT6. Constitutive overexpression of
PGC-1b in macrophages by retroviral
transduction or transgenesis downregu-
lates macrophage inflammatory re-
sponses induced by LPS, including IL-6
and IL-12 production, and amplifies
IL-4-induced alternative macrophage ac-
tivation markers, including arginase I and
dectin-1. Consistent with this role, RNAi
knockdown of PGC-1b levels reduced
the effects of IL-4 on metabolic pathways
and inflammatory cytokine production.
Thus, this new work suggests that this
transcription factor coactivator links oxi-
dative metabolism to anti-inflammatory
responses by potentiating IL-4 signals.
In tantalizing experiments, the authors
show that macrophages from mice ex-
pressing transgenic PGC-1b are primed
for alternative activation, and it will be in-
teresting to see how these mice respond7
P R E V I E W SFigure 1. Classical and alternative activation of macrophages are regulated by the induction of metabolic
programs
Macrophages can adopt distinct phenotypes in response to Th1 or Th2 cytokines (IFN-g/TNF-a vs IL4/IL13),
which elicit proinflammatory or reparative responses. The classical activation phenotype includes production
of nitric oxide, TNFa, and interleukins 1, 6, and 12. The alternative activation phenotype is characterized by
expression of dectin-1 and the mannose receptor and secretion of IL-10, IL-1 receptor antagonist (RA), the
resistin-like protein FIZZ1 (Found in the Inflammatory Zone), the chitinase YM1, and collagen. These pheno-
types are directly linked to the metabolic state of the macrophage and are coordinated by the opposing ac-
tions of transcription factors and their coactivators, including HIF1a, STAT6, and PGC-1b. Hence manipulation
of cellular metabolic pathways may have far-reaching consequences for directing immune responses.in inflammatory models. Such experi-
ments will be critical for full appreciation
of the in vivo implications of this process.
These findings provide a potential
mechanism by which therapies that pro-
mote utilization of fatty acids, such as
fibric acids and thiazolidinediones, may
also prime the immune system for resolu-
tion and repair. The hypolipidemic fibric
acid drugs, which are PPAR-a activators,
stimulate the expression of genes in-
volved in fatty-acid b oxidation but also
have an unexplained impact on vascular
wall inflammation (Fruchart et al., 2001).
The statins, another class of lipid-lower-
ing drugs that act by inhibiting the rate-
limiting enzyme in cholesterol synthesis,
3-hydroxy-3methylglutaryl-coenzyme A
(HMG-CoA) reductase, also have pleio-
tropic anti-inflammatory actions on
diseases including rheumatoid arthritis,
asthma, stroke, and transplant rejection.
Recent data suggest that these effects8may be through promotion of Th2 im-
mune responses and alternative activa-
tion of macrophages rather than lipid
regulation. The anti-inflammatory actions
of statins were shown to be dependant on
STAT6 and PPAR-a (Arora et al., 2006;
Paumelle et al., 2006), and the new work
by Vats et al. links these effects to the
induction of PGC-1b and mitochondrial
oxidative metabolism. Interestingly, an
essential role for another transcrip-
tion factor, hypoxia inducible factor-1a
(HIF-1a), in the regulation of effector
responses of classically activated macro-
phages and macrophage glycolytic ca-
pacity has also been reported (Cramer
et al., 2003). Together, these studies
highlight the important ability of transcrip-
tional activators to facilitate ‘‘crosstalk’’
between diverse cellular programs such
as metabolic and immune responses.
However, despite the potential benefit
of alternatively activating macrophagesfor the promotion of humoral immune re-
sponses and resolution of chronic inflam-
matory diseases such as atherosclerosis
and autoimmunity, these cells may also
be detrimental to other conditions by con-
tributing to scarring, persistence of infec-
tion, and the growth of tumors (Wynn,
2004). The future challenge will be to fully
understand the mechanisms that define
diverse macrophage phenotypes and to
control their generation appropriately.
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